Liver transplantation for primary sclerosing cholangitis.
Although the development of interventional radiology and biliary surgical techniques has prolonged the survival time of patients with primary sclerosing cholangitis, liver transplantation remains the only effective treatment for patients with primary sclerosing cholangitis with liver cirrhosis. Several prognostic survival models have been establised for this disease, and the efficacy of actual liver transplantations has been reported in comparison with these survival models. One- and 5-year actuarial patient survivals after liver transplantation for primary sclerosing cholangitis were shown to be greater than and approximately equal to 90%, respectively. An association with cholangiocarcinoma is the most adverse factor affecting survival after liver transplantation for primary sclerosing cholangitis, while the association of inflammatory bowel disease or previous bili-ary surgery does not adversely affect the outcome of the liver transplantation. Recurrent sclerosing cholangitis is an important issue for posttransplant patients with primary sclerosing cholangitis, and occurs in 10%-20% of such patients. Although our understanding of recurrent sclerosing cholangitis is still in the early stages, its potential occurrence indicates the need for a longer follow-up period after liver transplantation.
Sekido
H
H
Second Department of Surgery, Yokohama City University School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama 236-0004, Japan.
Takeda
K
K
Morioka
D
D
Kubota
T
T
Tanaka
K
K
Endo
I
I
Nagahori
K
K
Togo
S
S
Shimada
H
H
D001650:Bile Duct Neoplasms / Q000209:etiology / Q000601:surgery; D001653:Bile Ducts, Intrahepatic; D018281:Cholangiocarcinoma / Q000209:etiology / Q000601:surgery; D015209:Cholangitis, Sclerosing / Q000150:complications / Q000601:surgery*; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000209:etiology / Q000601:surgery; D008103:Liver Cirrhosis / Q000209:etiology / Q000601:surgery; D016031:Liver Transplantation; D012008:Recurrence; D016019:Survival Analysis; D016896:Treatment Outcome